Management of thrombotic microangiopathy after hematopoietic cell transplantation: A position statement of ThREG (Turkish Hematology Research and Education Group). (December 2021)

• Record Type: Journal Article
• Authors: Kaya, Ali Hakan; Tekgunduz, Emre
• Is Part Of: Transfusion and apheresis science. Volume 60:Number 6(2021)
• Publication Date: 2021-12
• Subjects: Hematopoietic stem cell transplantation -- Thrombotic microangiopathy -- Thrombocytopenia; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2021.103313
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: Hematopoietic stem cell transplantation associated-thrombotic microangiopathy (TA-HCT) is one of the early complications of endothelial origin in the course of HCT. Endothelial damage to the microvascular structure and the platelet-rich microthrombi, which are formed as a result of accompanying complement activation, constitute the main pathological conditions resulting TA-TMA. Early diagnosis and management are of utmost importance to prevent multi-organ failure and death. This review summarizes the current understanding of TA-TMA regarding pathogenesis, definition, differential diagnosis, risk factors, surveillance for early diagnosis and management.